- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
At a press conference earlier today in Providence, Rhode Island, U.S. Attorney General Eric Holder was peppered with questions about medical marijuana. This is understandable, given that a month ago U.S. Attorney Peter Neronha sent a letter to Rhode Island Governor Lincoln Chafee and other state officials threatening:
[C]ivil or criminal remedies against those individuals and entities who set up marijuana growing facilities and dispensaries.
Holder responded that the White House policy outlined in the Ogden memo, which de-emphasized federal interference, “made sense given…the limited resources that we have.” Addressing the obvious discord between policy and practice, Holder said he was working in Rhode Island and other parts of the country to “clarify what this policy means and how the policy can be implemented.”
Holder further stated that:
What we have to do is try to effectuate that policy in a way that we give comfort to somebody who is using it appropriately.
Patient advocates are pleased that Holder wants to clarify this glaring contradiction in Justice Department policy. Rhode Island was not the only state to endure threats from U.S. Attorneys. The Justice Department sent letters to local and state officials in at least 10 different states. These letters and the ongoing federal Drug Enforcement Administration (DEA) raids occurring across the country have had a devastating impact on patients’ rights and safe access. Programs have been suspended not only in Rhode Island, but in Arizona and New Jersey as well. State and local laws were arguably curtailed by federal interference in California, Montana and Washington.
Holder did say that he wants the process of clarifying federal policy to involve “dialog” and “communication.” We certainly hope he includes patients -- the ones directly affected by these policies -- in the dialog. But, we’re not waiting for his invitation so stay tuned for ways to make your voice heard.